Sun Pharmaceutical Industries Limited(IN:SUNPHARMA)
₹1,872.30+2.25 (+0.12%)
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited stock drug pipeline
₹1,872.30
At close:+2.25 (+0.12%)
Want to see IN:SUNPHARMA full AI Analyst Report?
Sun Pharmaceutical Industries Limited (SUNPHARMA) Drug Pipeline
24 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Sun Pharmaceutical Industries Limited (IN:SUNPHARMA) have in its pipeline
Sun Pharmaceutical Industries Limited IN:SUNPHARMA is currently developing the following drugs: Gl0034, Gl0034 Dose Level 1, Gl0034 Dose Level 2, Gl0034 Dose Level 3, Gl0034 Dose Level 4, Gl0034 Dose Level 5, Gl0034 Dose Level 6, Vehicle, Reformulated Levulan Kerastick Containing Aminolevulinic Acid Hydrochloride, 20%, Blue Light Photodynamic Therapy Illuminator Device, Blu-U Model 4170E., Reformulated Levulan Kerastick Containing Aminolevulinic Acid Hydrochloride, 20%, Vehicle Containing Excipients Only Without Active Ingredient, Blue Light Photodynamic Therapy Illuminator Device, Blu-U Model 4170E., Deuruxolitinib, Sonidegib Phosphate Capsules, Trifarotene Cream 0.005%, Aklief Cream Us Reference Listed Drug, Aklief Cream Canadian Reference Product, Ruxolitinib Topical Cream 1.5%, Opzelura Cream, Clindamycin Phosphate, Adapalene, And Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, Cabtreo Topical Gel, Tildrakizumab 100 Mg, Winlevi Cream 1%, Winlevi 1% Cream, Winlevi 1% & Adapalene 0.3% Gel, Winlevi 1% & Duac Gel, Ctp-543, Brinzolamide Ophthalmic Suspension, Azopt, Tild Sub-Cutaneous Injection, Scd-044_Dose 1, Scd-044_Dose 2, Scd-044_Dose 3, Mm-Ii Dose I, Mm-Ii Dose Ii, Mm-Ii Dose Iii, Cequatm Ophthalmic Solution, Clindamycin Phosphate, Clindamycin Phosphate Rld, Tild, Etanercept, Tildrakizumab, Sdp-133, Lumigan, Part 2: Double-Blind Active Treatment Extension, Tildrakizumab, Injections Of Tildrakizumab, Sunpg18_07 I, Sunpg18_07 Ii, Zero-Dose, 90 Mcg Of Proair Hfa, 180 Mcg Of 90 Mcg Of Proair Hfa, 90 Mcg Of Albuterol Sulfate Inhalation Aerosol, Halobetasol Propionate, Treatment With Halobetasol Propionate 0.05% Topical Spray, Vehicle, Isv-305, Halobetasol Topical Lotion. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

